What it sells
We teach your immune system to attack and cure cancer
Business model breakdown
Trigger: what makes them buy now?
First-generation CAR-T limits: toxicity, preconditioning chemo, exhaustion/relapse, solid tumors unreachable, manufacturing bottleneck and cost.
Workflow: what inputs become what output?
Next-generation engineered T-cell receptor platform (MARC, Modular Actuation Receptor Complex) with separate targeting and signaling, on/off control; therapeutic programs in pipeline.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2023 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.